Maravai LifeSciences Q4 revenue drops less than expected

Reuters02-26
Maravai LifeSciences Q4 revenue drops less than expected

Overview

  • Life science reagents provider reported smaller-than-expected drop in Q4 revenue

  • Adjusted EBITDA for Q4 beat analyst expectations

  • Revenue decline due to reduced CleanCap orders for vaccine programs

Outlook

  • Maravai expects full-year 2026 revenue between $200 mln and $210 mln

  • Company projects full-year 2026 Adjusted EBITDA between $18 mln and $20 mln

Result Drivers

  • CLEANCAP ORDERS - TriLink segment revenue fell 17.4% in Q4 due to reduced CleanCap orders for vaccine programs

  • HCP KITS DEMAND - Cygnus segment revenue increased 4.1% in Q4 driven by strong demand for HCP kits

  • COST REDUCTION - Positive Adjusted EBITDA in Q4 attributed to organizational restructuring and cost reduction

Company press release: ID:nBwpLk9Ca

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$49.90 mln

$49.05 mln (11 Analysts)

Q4 Net Income

-$63 mln

Q4 Adjusted EBITDA

Beat

$500,000

-$4.02 mln (10 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $4.50, about 44.2% above its February 24 closing price of $3.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment